STM JOURNALS

International Journal of
Cell Biology and Cellular Functions

Volume 2, Issue 2, 2024
July–December
DOI: 10.37591/IJCBCF

https://journals.stmjournals.com/ijcbcf/

Review IJCBCF

Epidermolysis Bullosa and Its Role in Cervical Cancer: An Overview

Jugal Jaiswal*

Abstract

Epidermolysis Bullosa *is a group of uncommon genetic disorders that primarily affect the skin and mucous membranes. It is marked by severe skin fragility and the formation of blisters even after minor trauma. Traditionally, the focus of* Epidermolysis Bullosa *research has been on its dermatological manifestations, which include recurrent blistering, scarring, and the potential for infections due to the compromised skin barrier. However, recent advancements in* Epidermolysis Bullosa *research have shifted attention to its broader implications, particularly its potential link to certain types of cancer, with cervical cancer emerging as one of the most notable associations. Studies suggest that individuals with certain forms of* Epidermolysis Bullosa*, especially those with recessive dystrophic* Epidermolysis Bullosa*, may be at heightened risk for developing cancers, including cervical cancer. This increased susceptibility is thought to be due to chronic skin damage, prolonged inflammation, and the role of genetic mutations in* Epidermolysis Bullosa *that may contribute to an environment conducive to oncogenic processes. For instance, in recessive dystrophic* Epidermolysis Bullosa*, mutations in the collagen VII gene result in abnormal skin structures that could potentially trigger cellular pathways leading to malignancy. This article aims to investigate the mechanisms that contribute to the heightened risk of cervical cancer in individuals with* Epidermolysis Bullosa*. By examining the molecular pathways involved in* Epidermolysis Bullosa *and their intersection with carcinogenesis, it highlights how defective skin integrity and persistent tissue damage could contribute to the development of cervical cancer. Furthermore, the paper explores the risk factors specific to* Epidermolysis Bullosa *patients, emphasizing the need for regular cancer screenings and early detection in these vulnerable populations. Understanding these connections is essential for enhancing clinical care and creating preventive strategies for patients with* Epidermolysis Bullosa.

Keywords: *Epidermolysis Bullosa*, genetic, collagen VII, cell, cervical cancer

INTRODUCTION

Epidermolysis Bullosa (EB) is categorized into three main types: simplex, junctional, and dystrophic, each linked to distinct genetic mutations that primarily affect structural proteins, such as collagen. These mutations disrupt the integrity of the skin, making it prone to blistering from minor trauma. While EB's primary impact is on the skin, it also affects mucous membranes, particularly in areas like the esophagus and genital regions, leading to additional complications. Recent research has suggested an increased cancer risk among EB patients, particularly in relation to cervical cancer. This association is intriguing, as cervical cancer is closely linked to persistent infections with high-risk strains of human papillomavirus (HPV), a major oncogenic factor. The chronic skin and mucosal damage in EB patients could facilitate prolonged inflammation and cellular changes, potentially creating an environment conducive to HPV infection and

***Author for Correspondence**
Jugal Jaiswal
E-mail: jugalsinghania8@gmail.com

Student, Department of Biotechnology, IILM University Greater Noida, Uttar Pradesh, India

Received Date: November 30, 2024
Accepted Date: December 05, 2024
Published Date: December 26, 2024

Citation: Jugal Jaiswal. *Epidermolysis Bullosa* and Its Role in Cervical Cancer: An Overview. International Journal of Cell Biology and Cellular Functions. 2024; 2(2): 14–18p.

subsequent cancer development. This connection offers significant opportunities for further research [1].

UNDERSTANDING EB

Classification and Pathophysiology

EB is a group of genetic disorders classified into several types based on the level of skin cleavage and the specific genetic mutations involved. The primary types are simplex, junctional, and dystrophic EB, each associated with mutations in different genes encoding structural proteins that are critical for maintaining skin integrity. For example, EB simplex results from mutations in the keratin genes, while junctional and dystrophic types are linked to mutations in genes encoding collagen and other extracellular matrix components. The pathophysiology of EB is rooted in these genetic mutations, which disrupt the normal formation and function of the proteins responsible for the cohesion and stability of the skin and mucous membranes [2]. As a result, affected individuals experience extreme skin fragility, with blisters and wounds forming easily, even from minimal trauma. In addition to the skin, mucosal surfaces, including the mouth, esophagus, and genital areas, are often involved, leading to pain, difficulty swallowing, and chronic ulcers. This fragility leads to recurrent wounds that are prone to infection, persistent inflammation, and scarring. Chronic inflammation can exacerbate tissue damage and may contribute to the development of other complications, such as an increased susceptibility to cancers, particularly in areas with frequent tissue damage and exposure to environmental factors like HPV [3].

Clinical Manifestations

The clinical presentation of EB varies widely, from mild blistering in EB simplex to severe forms that may lead to significant disability and complications. For instance, mucosal involvement, especially in the genital area, causes disruptions to normal cellular architecture, creating complications that may predispose individuals to malignancies are shown in Table 1.

Table 1. Overview of research on MIF as a marker and therapeutic target in skin inflammation.

Study Year	Study Title	Key Findings
2021	Role of MIF in inflammatory processes	MIF was found to initiate pro-inflammatory cytokine secretion in EB models.
2020	MIF and its involvement in skin inflammation	Increased MIF levels correlate with the severity of skin inflammation in EB patients.
2019	MIF as a biomarker for chronic inflammation	MIF expression levels serve as a reliable biomarker for assessing inflammatory activity in EB.
2022	Therapeutic targets in EB	Blocking MIF signaling pathways reduced inflammation and improved healing in EB models.
2018	The functions of MIF in skin diseases	MIF participates in the regulation of inflammatory responses in various skin disorders, including EB.

Cervical Cancer: Epidemiology and Pathogenesis

Cervical cancer is essentially resulting from a persistent infection with high-risk strains of HPV, of which types 16 and 18 accounts for most of all cases. The oncogenic process is mediated through viral proteins that interfere with host cell cycle control to deliver aberrant cellular proliferation and ultimately malignancy is shown in Figure 1.

HPV and Immunological Factors

Immunity plays a crucial role in the body's defense against infections, including those caused by the HPV. Under normal circumstances, the immune system effectively identifies and eliminates HPV infections through both innate and adaptive immune responses. The body's immune cells, such as T-cells and natural killer cells, target and destroy infected cells, while antibodies can neutralize the virus, preventing further infection. However, individuals with severely impaired immune systems, whether due to chronic inflammatory conditions or inherited disorders like EB, may face difficulties in mounting an adequate immune response to HPV [4].



Figure 1. Cellular level disease image.

In EB, chronic skin damage and inflammation weaken the body's ability to heal and defend against infections, including viral ones. The continuous cycle of injury, inflammation, and healing in EB patients can lead to immune dysregulation, impairing the function of immune cells that are critical for combating infections. Furthermore, the persistent mucosal damage, particularly in the genital and cervical regions, increases the likelihood of HPV exposure and infection. In individuals with EB, the compromised immune system may be unable to adequately control HPV, allowing the virus to persist and potentially lead to oncogenic changes. This combination of impaired immunity and chronic inflammation contributes to an increased risk of HPV-related cancers, including cervical cancer, in these vulnerable populations [5].

THE INTERRELATION BETWEEN EB AND CERVICAL CANCER

Mucosal Involvement in EB

Patients with EB often experience significant issues with mucosal surfaces, particularly in sensitive areas, such as the genital region. The constant blistering and scarring, hallmarks of EB, lead to chronic irritation and inflammation, which are key factors in the development of dysplasia – a precancerous condition where normal cells begin to show abnormal growth patterns. Over time, this persistent cycle of injury and repair can disrupt the normal architecture of the epithelial tissue, leading to structural changes that favor the onset of malignancies [6].

In EB, the blisters and subsequent scarring cause ongoing trauma to the mucosal surfaces, particularly in the genital and cervical areas, which are highly susceptible to HPV infection. The inflammation that accompanies these injuries can lead to the activation of signaling pathways that promote cell proliferation, survival, and genomic instability, which are critical steps in the development of cancer. The constant tissue damage and healing process can also impair the normal immune response, leaving the tissue more vulnerable to infections and carcinogenic agents like HPV.

This architectural disruption of the epithelium creates an environment conducive to carcinogenesis. As normal cellular processes are altered, the risk of malignant transformations increases, particularly in areas with chronic irritation and compromised immune function. Therefore, individuals with EB, especially those with mucosal involvement, are at a significantly higher risk of developing HPV-related cancers, including cervical cancer [7].

Immune Impairment

Chronic tissue damage, coupled with potential immune dysregulation, creates a "double whammy" scenario for patients with EB, significantly increasing their predisposition to cancer. The constant cycle of skin and mucosal injury in EB leads to cellular stress, inflammation, and impaired tissue repair, which can initiate or accelerate malignant transformation. As cells repeatedly undergo injury and regeneration, the risk of genetic mutations and abnormalities increases, contributing to the development of dysplasia and, eventually, cancer.

At the same time, the immune system in EB patients may be compromised due to the ongoing inflammatory environment and structural damage to immune surveillance mechanisms. Chronic inflammation can disrupt the normal functioning of immune cells, reducing their ability to detect and eliminate cancerous or virus-infected cells. This immune dysregulation impairs the body's capacity to combat infections, including those caused by high-risk strains of HPV, which are known to cause cervical cancer.

The combination of chronic tissue damage and weakened immune responses leaves EB patients vulnerable to persistent HPV infections, which can lead to the development of cervical cancer. This increased susceptibility underscores the importance of regular screenings, early detection, and vigilant monitoring for EB patients, especially those with mucosal involvement, to mitigate the heightened risk of HPV-related cancers [8].

Clinical Observations and Studies

While numerous studies have highlighted the increased incidence of various malignancies in patients with EB, there is a notable gap in data specifically addressing cervical malignancies in this population. The chronic inflammatory state and ongoing tissue damage in EB patients, particularly in mucosal areas like the genital and cervical regions, create an environment that may increase the risk of cancer development. However, due to the rarity of these conditions and limited research focused on cervical cancer, the exact prevalence and mechanisms remain underexplored.

Given the unique vulnerability of EB patients to both chronic inflammation and immune dysregulation, it is crucial to consider these individuals at higher risk for HPV infections, which are strongly associated with cervical cancer. The combination of this chronic inflammation, tissue disruption, and potential immune impairment may predispose EB patients to malignant transformations, particularly in the cervical region.

As a result, there is a compelling need for more comprehensive surveillance and screening strategies tailored to this population. Regular cervical screenings, including Pap smears and HPV testing, should be considered standard practice for EB patients, particularly those with mucosal involvement. Early detection and intervention could significantly improve outcomes by identifying precancerous changes before they progress to cervical cancer, addressing this overlooked risk within the EB patient population [9].

Preventive Measures and Screening

For patients with EB, regular gynecological check-ups and vaccinations against HPV should be strongly encouraged as preventive measures to reduce the risk of cervical cancer. Due to chronic skin damage, persistent inflammation, and potential immune dysregulation inherent in EB, particularly in mucosal areas, such as the genital and cervical regions, these individuals are at heightened risk for persistent HPV infections, which can lead to cervical cancer. Regular screenings, including Pap smears and HPV tests, can help detect early signs of cervical dysplasia, allowing for timely intervention.

Additionally, healthcare providers must exercise heightened vigilance regarding the increased risk of cervical cancer in EB patients, especially those with mucosal involvement. Given the combination of chronic irritation, tissue damage, and the potential for HPV infection, these patients may be more susceptible to oncogenic processes. Practitioners should be proactive in identifying at-risk patients, recommending appropriate screenings, and offering HPV vaccination to prevent infection. By incorporating these strategies into routine care, the incidence of cervical cancer in EB patients can be reduced, improving their overall health outcomes and quality of life [10].

CONCLUSIONS

EB is traditionally regarded as a dermatological condition, primarily characterized by extreme skin fragility, blistering, and scarring. However, its implications extend far beyond the skin, particularly in

relation to the increased risk of cervical cancer. The chronic inflammation and repeated tissue damage associated with EB, especially in mucosal areas, such as the genital and cervical regions, create a unique and potentially harmful environment. This ongoing irritation, along with the loss of normal immunological regulatory control due to the disease's impact on immune cell function, elevates the risk of malignant transformations.

In individuals with EB, the persistent breakdown of skin and mucosal barriers leads to ongoing inflammation, which can alter cellular environments, promoting dysplasia or precancerous changes in affected tissues. The immune dysregulation associated with chronic inflammation further compromises the body's ability to fight off infections, such as HPV, a leading cause of cervical cancer. This combination of factors makes EB patients particularly vulnerable to the carcinogenic effects of HPV, significantly increasing their risk of developing cervical cancer.

Although awareness of this risk is increasing, additional research is needed to thoroughly understand the link between EB and cervical cancer. A deeper understanding will help refine screening protocols, allowing for earlier detection and better prevention strategies tailored to the specific needs of EB patients. Healthcare providers must remain vigilant, consistently monitoring EB patients for signs of cervical dysplasia or cancer and adapting their care strategies accordingly. This includes not only offering regular screenings but also ensuring appropriate interventions, such as HPV vaccination to mitigate the risk of cervical cancer in this high-risk population. With greater awareness and research, healthcare providers can improve the quality of life and long-term health outcomes for individuals with EB, addressing both their dermatological and oncological needs.

REFERENCES

1. Vieira AR. Basis of inheritance in humans. Monogr Oral Sci. 2021;30:1–19. doi: 10.1159/000520765.
2. du Rand A, Hunt JMT, Feisst V, Sheppard HM. Epidermolysis bullosa: a review of the tissue-engineered skin substitutes used to treat wounds. Mol Diagn Ther. 2022;26(6):627–643. doi: 10.1007/s40291-022-00613-2
3. Ahmed AR, Kalesinskas M, Kooper-Johnson S. Paraneoplastic autoimmune Laminin-332 syndrome (PALS): Anti-Laminin-332 mucous membrane pemphigoid as a prototype. Autoimmun Rev. 2023;22(10):103444.
4. Boeira VL, Souza ES, Rocha Bde O, Oliveira PD, Oliveira Mde F, Rêgo VR, et al. Inherited epidermolysis bullosa: clinical and therapeutic aspects. An Bras Dermatol. 2013;88(2):185–98. doi: 10.1590/S0365-05962013000200001
5. Holl J, Kowalewski C, Zimek Z, Fiedor P, Kaminski A, Oldak T, et al. Chronic diabetic wounds and their treatment with skin substitutes. Cells. 2021;10(3):655.
6. McCance DJ, et al. The role of HPV in cervical cancer: the importance of early detection and prevention. J Gynec Obstet. 2018;81(5):377–89.
7. Has C, Nyström A, Amir Hossein Saeidian, Bruckner-Tuderman L, Jouni Uitto. Epidermolysis bullosa: molecular pathology of connective tissue components in the cutaneous basement membrane zone. Matrix Biol. 2018;71–72:313–29.
8. Danescu S, Negrutiu M, Has C. Treatment of epidermolysis bullosa and future directions: a review. Dermatol Therapy. 2024;14(8):2059–75.
9. Bruckner-Tuderman L. Newer treatment modalities in epidermolysis bullosa. Ind Dermatol Online J. 2019;10(3):244–50. doi: 10.4103/idoj.IDOJ_287_18
10. Sait H, Srivastava S, Saxena D. Integrated management strategies for epidermolysis bullosa: current insights. Int J Gen Med. 2022;15:5133–44.

